Q3 2018 EPS Estimates for Edwards Lifesciences Corp (EW) Increased by Analyst

Edwards Lifesciences Corp (NYSE:EW) – Stock analysts at Jefferies Financial Group increased their Q3 2018 earnings per share (EPS) estimates for shares of Edwards Lifesciences in a report issued on Tuesday, September 4th. Jefferies Financial Group analyst R. Denhoy now forecasts that the medical research company will post earnings per share of $1.01 for the quarter, up from their prior forecast of $1.00. Jefferies Financial Group has a “Buy” rating and a $168.00 price target on the stock. Jefferies Financial Group also issued estimates for Edwards Lifesciences’ Q4 2018 earnings at $1.18 EPS and FY2020 earnings at $6.12 EPS.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 26th. The medical research company reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. Edwards Lifesciences had a return on equity of 29.11% and a net margin of 19.59%. The firm had revenue of $972.00 million during the quarter, compared to the consensus estimate of $968.32 million. During the same quarter in the prior year, the firm posted $1.08 EPS. The business’s revenue was up 10.0% on a year-over-year basis.

Other equities research analysts have also recently issued research reports about the company. ValuEngine cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 8th. Royal Bank of Canada upped their price objective on Edwards Lifesciences to $145.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 23rd. JPMorgan Chase & Co. upped their price objective on Edwards Lifesciences from $133.00 to $150.00 and gave the stock a “neutral” rating in a research note on Friday, July 27th. Raymond James assumed coverage on Edwards Lifesciences in a research note on Thursday, May 31st. They set an “outperform” rating and a $152.00 price objective on the stock. Finally, Citigroup upped their price objective on Edwards Lifesciences from $115.00 to $118.00 and gave the stock a “sell” rating in a research note on Tuesday, July 31st. One analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have assigned a buy rating to the company. Edwards Lifesciences currently has a consensus rating of “Buy” and an average target price of $152.45.

NYSE:EW opened at $140.55 on Friday. Edwards Lifesciences has a twelve month low of $100.20 and a twelve month high of $156.87. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.86 and a quick ratio of 1.47. The company has a market cap of $29.27 billion, a price-to-earnings ratio of 32.97, a PEG ratio of 1.93 and a beta of 0.57.

A number of institutional investors and hedge funds have recently bought and sold shares of EW. Bank Hapoalim BM increased its position in Edwards Lifesciences by 10.4% during the 2nd quarter. Bank Hapoalim BM now owns 3,730 shares of the medical research company’s stock worth $543,000 after buying an additional 350 shares during the period. Janney Montgomery Scott LLC increased its position in Edwards Lifesciences by 2.2% during the 2nd quarter. Janney Montgomery Scott LLC now owns 16,336 shares of the medical research company’s stock worth $2,378,000 after buying an additional 355 shares during the period. Wendell David Associates Inc. increased its position in Edwards Lifesciences by 4.0% during the 2nd quarter. Wendell David Associates Inc. now owns 9,548 shares of the medical research company’s stock worth $1,390,000 after buying an additional 363 shares during the period. Park Avenue Securities LLC increased its position in Edwards Lifesciences by 9.6% during the 2nd quarter. Park Avenue Securities LLC now owns 4,411 shares of the medical research company’s stock worth $645,000 after buying an additional 387 shares during the period. Finally, Tyers Asset Management LLC increased its position in Edwards Lifesciences by 6.1% during the 2nd quarter. Tyers Asset Management LLC now owns 6,832 shares of the medical research company’s stock worth $995,000 after buying an additional 392 shares during the period. Institutional investors and hedge funds own 82.12% of the company’s stock.

In related news, VP Larry L. Wood sold 6,300 shares of the stock in a transaction on Friday, June 15th. The stock was sold at an average price of $151.86, for a total value of $956,718.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Scott B. Ullem sold 25,000 shares of the stock in a transaction on Tuesday, July 3rd. The shares were sold at an average price of $145.67, for a total value of $3,641,750.00. Following the completion of the sale, the chief financial officer now owns 41,265 shares in the company, valued at approximately $6,011,072.55. The disclosure for this sale can be found here. In the last 90 days, insiders sold 122,075 shares of company stock worth $17,626,656. 1.84% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Recommended Story: Hedge Funds

Earnings History and Estimates for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply